IN THIS ISSUE
Researchers from the University of Toronto have published an overview of clinical trial and health data transparency across the Americas. We speak to the report authors to find out more. Plus, we examine the manufacturing challenges associated with gene and cell therapies, and explore how Amazon’s Pillpack acquisition could rattle the industry.
Also, we take a look at the evolving role of biomarkers in cancer drug development, examine the highs and lows of hormone replacement therapy drugs, and find out how Verge Genomics employs proprietary genomic datasets to create some of the field’s largest, comprehensive sources for ALS and Parkinson’s data.
Finally, we explore what life sciences firms can achieve with AI, find out why setting practical parameters can help to provide more accurate regulatory resourcing, and we find out why cannabis branding will be key to grabbing the attention of consumers in fledgling markets.
Eloise McLennan, editor